AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03240835
Drug: cisplatin and docetaxel
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles.
Trial: NCT01934335
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00112138
Drug: gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02168946
Drug: Vabomere
RxNorm normalized name: Vabomere
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vabomere for IV injection, administered as a 2 g/2 g dose
Trial: NCT03340493
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
Trial: NCT00087204
Drug: becatecarin
RxNorm normalized name: Becatecarin
DrugBank: Becatecarin (DB06362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01852344
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mgs of methylphenidate or placebo to be administered one hour before task performance
Trial: NCT02307305
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)
Trial: NCT02296840
Drug: Hydrocodone-Acetaminophen
RxNorm normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
Trial: NCT01507545
Drug: MORAb-004
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MORAb-004 8mg per kg IV once a week
Trial: NCT02035072
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2
Trial: NCT02035072
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 100 mg/m2
Trial: NCT02997189
Drug: OTO-104
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg dexamethasone administered intratympanically
Trial: NCT02400112
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin powder administered locally, intraoperatively at site of open fracture
Trial: NCT03072511
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
Trial: NCT00317070
Drug: dimethyl sulfoxide
RxNorm normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravesical installation 50 ml
Trial: NCT00233636
Drug: Iressa (Gefitinib)
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01046643
Drug: Progesterone (P10) x90
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Trial: NCT01046643
Drug: Progesterone (P10) x10
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
Trial: NCT01030042
Drug: Irinotecan/Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.
Trial: NCT01898312
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe
Trial: NCT04156646
Drug: Balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
Trial: NCT04156646
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
Trial: NCT02443844
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical treatment for benign prostate hyperplasia
Trial: NCT04110834
Drug: itraconazole gel once daily
RxNorm normalized name: clindamycin
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
Trial: NCT04110834
Drug: itraconazole gel twice daily
RxNorm normalized name: clindamycin
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
Trial: NCT00002423
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002423
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002423
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02893722
Drug: atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
Trial: NCT00002423
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002423
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01157858
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mg every day orally
Trial: NCT01157858
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg every 28 days IM
Trial: NCT03687034
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
Trial: NCT03425799
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Trial: NCT03425799
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Trial: NCT01225406
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02976467
Drug: Fulacimstat (BAY1142524)
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
Trial: NCT00397228
Drug: ALTROPANE®
DrugBank: Altropane (DB04947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALTROPANE® SPECT imaging
Trial: NCT04302181
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
Trial: NCT00946270
Drug: CC-4047
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg capsules daily by mouth day 1 through day 28.
Trial: NCT00946270
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
Trial: NCT00946270
Drug: CC-4047
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg capsules daily by mouth day 1 through 21.
Trial: NCT02672839
Drug: LGD-6972 Solution
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of LGD-6972
Trial: NCT02672839
Drug: LGD-6972 Capsules
RxNorm normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg LGD-6972
Trial: NCT00306891
Drug: Cediranib
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg oral dose
Trial: NCT00306891
Drug: Cediranib 30 - 90 mg
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet dose escalation
Trial: NCT01757457
Drug: Intracoronary administration of an abciximab bolus during primary PCI
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Trial: NCT01757457
Drug: Intravenous administration of an abciximab bolus during primary PCI
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Trial: NCT00232570
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01511146
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin 85 mg/m2 in 10 minutes
Trial: NCT01511146
Drug: Mitomycin + Gemcitabine
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
Trial: NCT01161524
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg titrated up to 8-12 mg maximum; taken once daily.
Trial: NCT02499965
Drug: Ethyl Chloride Topical Aerosol Anesthetic
RxNorm normalized name: ethyl chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Trial: NCT02499965
Drug: Nature's Tears Sterile Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Trial: NCT00072969
Drug: Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02329535
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: vaginal caps 400 mg daily up to 36 weeks of gestation
Trial: NCT02365532
Drug: GS-6615
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-6615 tablets administered orally
Trial: NCT02365532
Drug: Placebo to match dofetilide
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to match dofetilide capsules administered orally
Trial: NCT02365532
Drug: Dofetilide
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information
Trial: NCT02172222
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172222
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04019496
Drug: antibodies against calcitonin-gene related peptide or its receptor
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
Trial: NCT01618656
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be administered at 4mg by mouth daily for four weeks.
Trial: NCT00695994
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
Trial: NCT00127218
Drug: niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-acting niacin daily for 18 months
Trial: NCT00695994
Drug: gemcitabine and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
Trial: NCT00650429
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
Trial: NCT01063205
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
Trial: NCT01063205
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
Trial: NCT00469014
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
Trial: NCT00469014
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7.
Trial: NCT00469014
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
Trial: NCT00469014
Drug: Thymoglobulin (ATG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Trial: NCT00469014
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
Trial: NCT00396227
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: vildagliptin as add-on to metformin
Trial: NCT00396227
Drug: thiazolidinedione (TZD)
RxNorm normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZD add-on to metformin
Trial: NCT00866294
Drug: paroxetine IR 10mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT00866294
Drug: paroxetine IR 20mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT00866294
Drug: matched placebo to paroxetine IR 10mg or 20mg
RxNorm normalized name: paroxetine mesylate 10 MG
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT00866294
Drug: Paroxetine CR 12.5mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT00866294
Drug: Paroxetine CR 25mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT00866294
Drug: matched placebo to paroxetine CR 12.5mg or 25mg
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT00299884
Drug: Lipitor 20 mg
RxNorm normalized name: Lipitor 20 MG Oral Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A/A for 6 weeks
Trial: NCT01052012
Drug: SABER-Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injectable Extended Release Solution; SABER-Bupivacaine /Once
Trial: NCT01052012
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injectable Solution; Bupivacaine HCl /Once
Trial: NCT03798561
Drug: Placebo TG
RxNorm normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TG
Trial: NCT00754429
Drug: losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan 50mg qd for 30 weeks.
Trial: NCT00754429
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5 mg q.d for 30 weeks.
Trial: NCT02973646
Drug: Entecavir or Tenofovir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
Trial: NCT02973646
Drug: Peginterferon Alfa-2B
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no